Adjuvia is a preclinical-stage biopharma developing oral nanoparticle formulations of astaxanthin to treat mitochondrial and cellular dysfunction underlying rare and chronic diseases. Its lead candidate, ATI‑105, uses a patented microalgae‑derived astaxanthin with enhanced bioavailability to reduce oxidative damage and restore cell function, and is in IND‑enabling studies for inherited mitochondrial disorders, while a second candidate, ATI‑106, targets neurodegenerative diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Mitochondrial and cellular dysfunction underlies many rare and chronic diseases, leading to oxidative stress, cellular damage, and organ failure. Existing therapies are limited, often failing to address the root cause or to provide systemic, orally available treatment options.
Solution
Adjuvia develops orally administered nanoparticle formulations of astaxanthin (ASX) to target mitochondrial dysfunction at its source. Their lead candidate, ATI‑105, delivers a highly bioavailable, systemically active antioxidant that spans cell membranes, reduces oxidative damage, and modulates signaling pathways to restore cellular function. The formulation is derived from Haematococcus pluvialis microalgae using a patented process that creates a novel molecular conformation of ASX, enhancing both potency and absorption. ATI‑105 is currently in IND‑enabling studies and is positioned as a potential frontline therapy for rare inherited mitochondrial diseases such as Friedreich’s ataxia and Leigh syndrome. A second pipeline candidate, ATI‑106, is being explored for Alzheimer’s and other neurodegenerative disorders.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to license or co‑develop oral mitochondrial therapeutics, as well as clinicians and healthcare systems treating patients with rare inherited mitochondrial disorders.
Features
- Proprietary oral nanoparticle delivery of astaxanthin with superior bioavailability compared to conventional ASX supplements
- Patented extraction and formulation method yielding a novel molecular conformation that enhances antioxidant activity
- Systemic distribution enabling treatment of mitochondrial dysfunction across multiple organ systems
- Scalable manufacturing process using microalgae (Haematococcus pluvialis) as a renewable source
- IND‑enabling preclinical data supporting safety and efficacy for rare mitochondrial disease indications
- Pipeline extension into neurodegenerative diseases (Alzheimer’s) with preclinical proof‑of‑concept studies